![](https://medcitynews.com/wp-content/uploads/sites/7/2022/02/50596808198_3b720dfccf_c.jpg)
BioNTech Buys Into Hot Area of Cancer R&D, Paying $170M for 2 Drug Assets
BioNTech’s alliance with DualityBio gives it two antibody drug conjugate (ADC) candidates, the most advanced of which is in mid-stage clinical development for solid tumors. It addresses the same target as a potential blockbuster AstraZeneca drug.